RenovoRx, Inc. (RNXT) analyst actions
Rating and price-target actions on RNXT in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the RNXT overview →
3 measured RNXT analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial | Press release | -3.33% | +1.48% | |
| Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial | Press release | +0.00% | -1.04% | |
| RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer | Press release | +2.88% | +3.68% |
Keep exploring
More RNXT: earnings → · SEC filings → · RNXT overview →